keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer biomarker

keyword
https://www.readbyqxmd.com/read/28734369/systematic-comparison-of-exosomal-proteomes-from-human-saliva-and-serum-for-the-detection-of-lung-cancer
#1
Yan Sun, Sha Liu, Zhi Qiao, Zhi Shang, Zhijun Xia, Xiaomin Niu, Liqiang Qian, Yan Zhang, Liuyin Fan, Cheng-Xi Cao, Hua Xiao
Circulating tumor exosomes harbor plenty of cancer biological information, which have emerged as promising targets for cancer early detection and diagnosis. Human serum and saliva are unique diagnostic body fluids, which contain numerous circulating exosomes. It is necessary to establish standardized isolation method and compare their proteome profiling for translational medicine. High abundant proteins in these body fluids were removed before exosomes isolation and obtained exosomes were further confirmed by morphology analysis and surface biomarker test...
August 22, 2017: Analytica Chimica Acta
https://www.readbyqxmd.com/read/28732214/crispr-cas9-technology-based-xenograft-tumors-as-candidate-reference-materials-for-multiple-eml4-alk-rearrangements-testing
#2
Rongxue Peng, Rui Zhang, Guigao Lin, Xin Yang, Ziyang Li, Kuo Zhang, Jiawei Zhang, Jinming Li
The echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (EML4-ALK) rearrangement is an important biomarker that plays a pivotal role in therapeutic decision making for non-small-cell lung cancer (NSCLC) patients. Ensuring accuracy and reproducibility of EML4-ALK testing by fluorescence in situ hybridization, immunohistochemistry, RT-PCR, and next-generation sequencing requires reliable reference materials for monitoring assay sensitivity and specificity...
July 18, 2017: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/28731711/identification-of-proteomic-features-to-distinguish-benign-pulmonary-nodules-from-lung-adenocarcinoma
#3
Simona G Codreanu, Megan D Hoeksema, Robbert J C Slebos, Lisa J Zimmerman, S M Jamshedur Rahman, Ming Li, Sheau-Chiann Chen, Heidi Chen, Rosana Eisenberg, Daniel C Liebler, Pierre P Massion
We hypothesized that distinct protein expression features of benign and malignant pulmonary nodules may reveal novel candidate biomarkers for the early detection of lung cancer. We performed proteome profiling by liquid chromatography-tandem mass spectrometry to characterize 34 resected benign lung nodules, 24 early stage untreated lung adenocarcinomas (ADCs) and biopsies of bronchial epithelium. Group comparisons identified 65 proteins that differentiate nodules from ADCs and normal bronchial epithelium, and 66 proteins that differentiate ADCs from nodules and normal bronchial epithelium...
July 21, 2017: Journal of Proteome Research
https://www.readbyqxmd.com/read/28731408/defining-the-biological-basis-of-radiomic-phenotypes-in-lung-cancer
#4
Patrick Grossmann, Olya Stringfield, Nehme El-Hachem, Marilyn M Bui, Emmanuel Rios Velazquez, Chintan Parmar, Ralph Th Leijenaar, Benjamin Haibe-Kains, Philippe Lambin, Robert Gillies, Hugo Jwl Aerts
Medical imaging can visualize characteristics of human cancer noninvasively. Radiomics is an emerging field that translates these medical images into quantitative data to enable phenotypic profiling of tumors. While radiomics has been associated with several clinical endpoints, the complex relationships of radiomics, clinical factors, and tumor biology are largely unknown. To this end, we analyzed two independent cohorts of respectively 262 North American and 89 European patients with lung cancer, and consistently identified previously undescribed associations between radiomic imaging features, molecular pathways, and clinical factors...
July 21, 2017: ELife
https://www.readbyqxmd.com/read/28731174/lhx3-is-an-early-stage-and-radiosensitivity-prognostic-biomarker-in-lung-adenocarcinoma
#5
Xin Lin, Yan Li, Jin Wang, Fei Han, Shuang Lu, Yu Wang, Wenjian Luo, Mingqian Zhang
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. We previously identified LHX3 as a new preferentially expressed gene in NSCLC. In the present study, we sought to determine its expression, the clinical relevance and the functional roles in NSCLC. LHX3 expression is sharply increased in carcinoma tissues compared to non-carcinoma tissues. Relational analysis reveals a significant association between LHX3 expression and clinical stage (n=172, p=0.032) or radiotherapy (n=167, p=0.022) of patients...
July 18, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28729763/serum-and-plasma-metabolomic-biomarkers-for-lung-cancer
#6
Nishith Kumar, Md Shahjaman, Md Nurul Haque Mollah, S M Shahinul Islam, Md Aminul Hoque
In drug invention and early disease prediction of lung cancer, metabolomic biomarker detection is very important. Mortality rate can be decreased, if cancer is predicted at the earlier stage. Recent diagnostic techniques for lung cancer are not prognosis diagnostic techniques. However, if we know the name of the metabolites, whose intensity levels are considerably changing between cancer subject and control subject, then it will be easy to early diagnosis the disease as well as to discover the drug. Therefore, in this paper we have identified the influential plasma and serum blood sample metabolites for lung cancer and also identified the biomarkers that will be helpful for early disease prediction as well as for drug invention...
2017: Bioinformation
https://www.readbyqxmd.com/read/28729729/a-novel-methodology-using-ct-imaging-biomarkers-to-quantify-radiation-sensitivity-in-the-esophagus-with-application-to-clinical-trials
#7
Joshua S Niedzielski, Jinzhong Yang, Francesco Stingo, Zhongxing Liao, Daniel Gomez, Radhe Mohan, Mary Martel, Tina Briere, Laurence Court
Personalized cancer therapy seeks to tailor treatment to an individual patient's biology. Therefore, a means to characterize radiosensitivity is necessary. In this study, we investigated radiosensitivity in the normal esophagus using an imaging biomarker of radiation-response and esophageal toxicity, esophageal expansion, as a method to quantify radiosensitivity in 134 non-small-cell lung cancer patients, by using K-Means clustering to group patients based on esophageal radiosensitivity. Patients within the cluster of higher response and lower dose were labelled as radiosensitive...
July 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28729397/the-igf1r-insr-inhibitor-bi-885578-selectively-inhibits-growth-of-igf2-overexpressing-colorectal-cancer-tumors-and-potentiates-the-efficacy-of-anti-vegf-therapy
#8
Michael P Sanderson, Marco H Hofmann, Pilar Garin-Chesa, Norbert Schweifer, Andreas Wernitznig, Stefan Fischer, Astrid Jeschko, Reiner Meyer, Jurgen Moll, Thomas Pecina, Heribert Arnhof, Ulrike Weyer-Czernilofsky, Stephan K Zahn, Günther R Adolf, Norbert Kraut
Clinical studies of pharmacological agents targeting the insulin like growth factor (IGF) pathway in unselected cancer patients have so far demonstrated modest efficacy outcomes, with objective responses being rare. As such, the identification of selection biomarkers for enrichment of potential responders represents a high priority for future trials of these agents. Several reports have described high IGF2 expression in a subset of colorectal cancers (CRC), with focal IGF2 amplification being responsible for some of these cases...
July 20, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28725482/systems-biology-driving-drug-development-from-design-to-the-clinical-testing-of-the-anti-erbb3-antibody-seribantumab-mm-121
#9
REVIEW
Birgit Schoeberl, Art Kudla, Kristina Masson, Ashish Kalra, Michael Curley, Gregory Finn, Emily Pace, Brian Harms, Jaeyeon Kim, Jeff Kearns, Aaron Fulgham, Olga Burenkova, Viara Grantcharova, Defne Yarar, Violette Paragas, Jonathan Fitzgerald, Marisa Wainszelbaum, Kip West, Sara Mathews, Rachel Nering, Bambang Adiwijaya, Gabriela Garcia, Bill Kubasek, Victor Moyo, Akos Czibere, Ulrik B Nielsen, Gavin MacBeath
The ErbB family of receptor tyrosine kinases comprises four members: epidermal growth factor receptor (EGFR/ErbB1), human EGFR 2 (HER2/ErbB2), ErbB3/HER3, and ErbB4/HER4. The first two members of this family, EGFR and HER2, have been implicated in tumorigenesis and cancer progression for several decades, and numerous drugs have now been approved that target these two proteins. Less attention, however, has been paid to the role of this family in mediating cancer cell survival and drug tolerance. To better understand the complex signal transduction network triggered by the ErbB receptor family, we built a computational model that quantitatively captures the dynamics of ErbB signaling...
2017: NPJ Systems Biology and Applications
https://www.readbyqxmd.com/read/28724602/the-clinical-and-prognostic-value-of-polo-like-kinase-1-in-lung-squamous-cell-carcinoma-patients-immunohistochemical-analysis
#10
Hefei Li, Haibo Wang, Zhenqing Sun, Qiang Guo, Hongyun Shi, Youchao Jia
Polo-like kinase 1 (PLK1) has been suggested to serve as oncogene in most human cancers. The aim of our study is to present more evidence about the clinical and prognostic value of PLK1 in lung squamous cell carcinoma patients. The status of PLK1 was observed in lung adenocarcinoma, lung squamous cell carcinoma and normal lung tissues through analyzing microarray data set (GEO accession number: GSE1213 and GSE 3627). PLK1 mRNA and protein expressions were detected in lung squamous cell carcinoma and normal lung tissues by using qRT-PCR and immunohistochemistry...
July 19, 2017: Bioscience Reports
https://www.readbyqxmd.com/read/28723670/quaking-5-suppresses-aggressiveness-of-lung-cancer-cells-through-inhibiting-%C3%AE-catenin-signaling-pathway
#11
Xuexia Zhou, Xuebing Li, Cuiyun Sun, Cuijuan Shi, Dan Hua, Lin Yu, Yanjun Wen, Feng Hua, Qian Wang, Qinghua Zhou, Shizhu Yu
Quaking-5 (QKI-5) belongs to the STAR (signal transduction and activation of RNA) family of RNA binding proteins and functions as a tumor suppressor in several human malignancies. In this study, we attempt to elucidate the role of QKI-5 in the pro-metastasis processes of lung cancer (LC) cells and the underlying mechanisms. We confirmed that QKI-5 was decreased in human LC tissues and cell lines, especially in high-metastatic cells. Moreover, QKI expression was positively correlated with LC patients' survival...
July 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28723655/long-non-coding-rna-tug1-as-a-potential-prognostic-biomarker-in-human-cancers-a-meta-analysis
#12
Peng-Ju Ma, Qing-Kai Guan, Lei Meng, Nan Qin, Jia Zhao, Bao-Zhe Jin
LncRNA taurine upregulated gene 1 (TUG1) is reportedly dysregulated in various cancers. We performed this meta-analysis to clarify the usefulness of TUG1 as a prognostic marker in malignant tumors. The PubMed, Medline, OVID, Cochrane Library, and Web of Science databases were searched from inception to Jan 11, 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between TUG1 expression and overall survival (OS). Odds ratios (ORs) were calculated to assess the association between TUG1 expression and pathological parameters...
July 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28721818/eurycoma-longifolia-a-potential-phytomedicine-for-the-treatment-of-cancer-evidence-of-p53-mediated-apoptosis-in-cancerous-cells
#13
Hnin Ei Thu, Zahid Hussain, Isa Naina Mohamed, Ahmad Nazrun Shuid
BACKGROUND: Eurycoma longifolia is a well-documented herbal medicine that has gained widespread recognition due to its versatile pharmacological activities including anticancer, anti-malarial, antimicrobial, antioxidant, aphrodisiac, anti-inflammatory, anxiolytic, anti-diabetic, anti-rheumatism and anti-ulcer. Plethora of in vitro and in vivo studies evidenced their excellent anti-proliferative and anticancer efficacy against various types of human cancers. OBJECTIVE: This review was aimed to critically analyze the therapeutic viability and anticancer efficacy of Eurycoma longifolia in the treatment of cancer and also to propose its molecular and translational mechanism of cytotoxicity against cancerous cells...
July 18, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28720841/novel-immunohistochemistry-based-signatures-to-predict-metastatic-site-of-triple-negative-breast-cancers
#14
Sergey Klimov, Padmashree Cg Rida, Mohammed A Aleskandarany, Andrew R Green, Ian O Ellis, Emiel Am Janssen, Emad A Rakha, Ritu Aneja
BACKGROUND: Although distant metastasis (DM) in breast cancer (BC) is the most lethal form of recurrence and the most common underlying cause of cancer related deaths, the outcome following the development of DM is related to the site of metastasis. Triple negative BC (TNBC) is an aggressive form of BC characterised by early recurrences and high mortality. Athough multiple variables can be used to predict the risk of metastasis, few markers can predict the specific site of metastasis...
July 18, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28718980/an-endogenous-dna-adduct-as-a-prognostic-biomarker-for-hepatocarcinogenesis-and-its-prevention-by-theaphenon-e-in-mice
#15
Ying Fu, Shana Silverstein, Justine N McCutcheon, Marcin Dyba, Raghu G Nath, Monika Aggarwal, Heidi Coia, Angela Bai, Jishen Pan, Jiji Jiang, Bhaskar Kallakury, Hongkun Wang, Yu-Wen Zhang, Giuseppe Giaccone, Aiwu Ruth He, Fung-Lung Chung
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, mainly because of its poor prognosis. A valid mechanism-based prognostic biomarker is urgently needed. γ-hydroxy-1,N(2) -propanodeoxyguanosine (γ-OHPdG) is an endogenously formed mutagenic DNA adduct derived from lipid peroxidation (LPO). We examined the relationship of γ-OHPdG with hepatocarcinogenesis in two animal models and its potential role as a prognostic biomarker for recurrence in HCC patients. Bioassays were conducted in the Xeroderma pigmentosum group A knockout mice (Xpa(-/-) ), and the diethylnitrosamine (DEN)-injected mice, both prone to HCC development...
July 18, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28718367/hbxip-suppression-reduces-cell-proliferation-and-migration-and-its-overexpression-predicts-poor-prognosis-in-non-small-cell-lung-cancer
#16
Yixuan Wang, Nan Li, Shuanlong Che, Tiefeng Jin, Junjie Piao, Shuangping Liu, Zhenhua Lin
Emerging evidence has demonstrated that the high expression of HBXIP has been correlated with many cancers. With evaluation of the functional role of HBXIP in non-small-cell lung cancer, the primary aim of this study is to investigate the correlation between HBXIP expression and the prognosis of non-small-cell lung cancer patients. The protein levels of HBXIP were detected using western blotting in non-small-cell lung cancer cells. Cell proliferation and migration assays were measured to evaluate the function of HBXIP in non-small-cell lung cancer cells...
July 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28717894/determination-of-ketones-and-ethyl-acetate-a-preliminary-study-for-the-discrimination-of-patients-with-lung-cancer
#17
Patricia Martín Santos, Miguel Del Nogal Sánchez, Ángel Pedro Crisolino Pozas, José Luis Pérez Pavón, Bernardo Moreno Cordero
In this work, ten possible volatile biomarkers of lung cancer (acetone, 2-butanone, ethyl acetate, 2-pentanone, 4-methyl-2-pentanone, 2-hexanone, 3-heptanone, 2-heptanone, 3-octanone, and 2-nonanone) have been analyzed to evaluate their different concentration levels in urine samples from lung cancer patients (n = 12) and healthy controls (n = 12). The volatile compounds were generated with a headspace autosampler and analyzed with a gas chromatograph equipped with a programmed temperature vaporizer and mass spectrometry detector (HS-PTV-GC-MS)...
July 17, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/28717179/genetic-polymorphisms-and-platinum-based-chemotherapy-treatment-outcomes-in-patients-with-non-small-cell-lung-cancer-a-genetic-epidemiology-study-based-meta-analysis
#18
Li-Ming Tan, Cheng-Feng Qiu, Tao Zhu, Yuan-Xiang Jin, Xi Li, Ji-Ye Yin, Wei Zhang, Hong-Hao Zhou, Zhao-Qian Liu
Data regarding genetic polymorphisms and platinum-based chemotherapy (PBC) treatment outcomes in patients with NSCLC are published at a growing pace, but the results are inconsistent. This meta-analysis integrated eligible candidate genes to better evaluate the pharmacogenetics of PBC in NSCLC patients. Relevant studies were retrieved from PubMed, Chinese National Knowledge Infrastructure and WANFANG databases. A total of 111 articles comprising 18,196 subjects were included for this study. The associations of genetic polymorphisms with treatment outcomes of PBC including overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) were determined by analyzing the relative risk (RR), hazard ration (HR), corresponding 95% confidence interval (CI)...
July 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28716896/poor-prognosis-indicated-by-venous-circulating-tumor-cell-clusters-in-early-stage-lung-cancers
#19
Vasudha Murlidhar, Rishindra M Reddy, Shamileh Fouladdel, Lili Zhao, Martin K Ishikawa, Svetlana Grabauskiene, Zhuo Zhang, Jules Lin, Andrew C Chang, Philip W Carrott, William R Lynch, Mark B Orringer, Chandan Kumar-Sinha, Nallasivam Palanisamy, David G Beer, Max S Wicha, Nithya Ramnath, Ebrahim Azizi, Sunitha Nagrath
Early detection of metastasis can be aided by circulating tumor cells (CTCs), which also show potential to predict early relapse. Due to the limited CTC numbers in peripheral blood in early stages, we investigated CTCs in pulmonary vein blood accessed during surgical resection of tumors. Pulmonary vein (PV) and peripheral vein (Pe) blood specimens from patients with lung cancer were drawn during the perioperative period and assessed for CTC burden using a microfluidic device. From 108 blood samples analyzed from 36 patients, PV had significantly higher number of CTCs compared to pre-operative Pe (p<0...
July 17, 2017: Cancer Research
https://www.readbyqxmd.com/read/28716463/combination-strategies-on-the-basis-of-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-where-do-we-stand
#20
REVIEW
Meng Qiao, Tao Jiang, Shengxiang Ren, Caicun Zhou
The era of immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies in the treatment of advanced non-small-cell lung cancer (NSCLC) is coming. Because of the lack of the definite biomarkers to select the optimal responders, only approximately 20% of patients with advanced NSCLC would respond to single checkpoint inhibitors-based immunotherapy. Moreover, primary or acquired resistance to conventional therapies is inevitable in most cases. Thus, combinations are pushed to move forward to be an alternative strategy and surely, it would be a future direction...
June 23, 2017: Clinical Lung Cancer
keyword
keyword
10953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"